The evidence does not support a viral etiology for primary biliary cirrhosis  by Selmi, Carlo
Controversies in HepatologyThe evidence does not support a viral etiology for primary
biliary cirrhosis
Carlo Selmi⇑
Department of Medicine, Autoimmunity and Metabolism Unit, IRCCS-Istituto Clinico Humanitas, Rozzano, Italy; Division of
Rheumatology Allergy and Clinical Immunology, University of California at Davis, Davis, CA, USAThe hypothesis that a human endogenous retrovirus (HERV) has a
causative role in primary biliary cirrhosis (PBC) has been a recur-
ring theme in the scientiﬁc literature on this complex autoim-
mune disease for over 12 years. With his group, Dr. Andrew
Mason has repeatedly reported ﬁndings in support of this fasci-
nating proposal – which is presented elsewhere in this issue of
the Journal. In a nutshell, epidemiological and experimental evi-
dence incriminate environmental factors in the development of
PBC, also supported by the proposed geoepidemiology gradient
and the numerous risk factors including recurrent urinary tract
infections [1].
First, the Mason group reported a high prevalence of anti-ret-
roviral antibodies in the serum of PBC patients [2]. Second,
electron microscopy images were presented in support of the
presence of viral particles in the lymph nodes of patients with
PBC [3]. Third, the co-culture of healthy cholangiocytes with
periportal lymph nodes from patients with PBC led to the expres-
sion of AMA-antigens on the cholangiocyte membrane [4], thus
mirroring what had been reported previously in the liver of
patients with PBC liver [5] and subsequently deﬁned as the result
of immune complex deposition [6]. A virus was then cloned in the
DNA obtained from lymph nodes of two patients with PBC, the
sequencing of which revealed a human endogenous retrovirus
sharing signiﬁcant homology with the mouse mammary tumor
virus (MMTV) [7]. Finally, the authors identiﬁed retroviral
sequences in one of the recently described murine models of
PBC as well as the integration of the virus in PBC cholangiocytes,
although these latter data were not published in extenso.
Based on these observations, the Mason group initiated a mul-
ticenter clinical trial of antiretroviral treatment in patients with
PBC, but this failed to reach the non histological endpoints com-
monly utilized in clinical trials in PBC, but instead utilized vari-
ables such as upper abdominal pain, that is rarely observed in
clinical practice and has not been well validated as an end point
in studies in PBC [8]. In the same trial, the inclusion of upper
abdominal pain is a concern, since it tends to be associated with
other biliary disorders such as primary sclerosing cholangitis.Journal of Hepatology 20
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ruses in PBC with signiﬁcantly contradictory results. First in 2004,
our own group was unable to detect the presence of MMTV using
multiple molecular and tissue markers in fresh liver or peripheral
blood cells from a large number patients with PBC [9]. Subse-
quently, as published in this journal in 2009, the presence of
MMTV sequences was demonstrated in healthy liver tissues
and in a variable proportion of samples from patients with
chronic liver disease with a variety of aetiologies, including pri-
mary liver cancer and PBC [10]. Albeit in contrast, these studies
did include a large number of clinical samples thus increasing
the power of the comparisons.
HERV result from ancestral infections and there are sequences
within the human genome resembling infectious retroviruses.
Following retrovirus integration into the genome, evolutionary
processes disabled their potential damaging effects through
mutations that prevent viral protein expression and virulence
[5]. The genetic sequences of infectious retroviruses encode sev-
eral proteins that, in order to facilitate viral replication, stimulate
the cells in which they are expressed and enable the virus to
evade an immune response. Similar proteins can be encoded by
HERV, a property that confers the potential to cause disease
[11]. Brieﬂy, HERV may induce pathology by: (i) disrupting genes
at their integration site; (ii) suppressing or stimulating the
immune response; or (iii) expressing accessory proteins that have
direct effects on the cells in which they are expressed. The main
hurdle to this scenario is that the integration sites of the vast
majority of HERV are identical in different individuals and it
becomes increasingly difﬁcult to propose that a given HERV can
cause a disease in one individual and not another, as we would
expect a strikingly high concordance for the clinical phenotype
among individuals. Similarly, one would also expect that HERV
might increase the neoplastic potential of chronic inﬂammation,
as exempliﬁed by occult hepatitis B infection or MMTV itself.
However, the incidence rates of hepatocellular carcinoma and
breast cancer in PBC are similar to other etiologies of liver cirrho-
sis [12] and to control women [13], respectively.
These observations raise major concerns for the proposed evi-
dence. Firstly, the virus sequence should be detected in all
somatic cells and not only (or mostly) in lymph nodes [7]. Second,
if we consider monozygotic twins, we should expect a full con-
cordance of viral integration and consequently, disease preva-
lence, which is not the case for PBC [14]. One possible
explanation could be a mechanism of gene silencing present in11 vol. 54 j 1315–1316
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the healthy twin, but we recently completed a genome-wide DNA
methylation analysis and found no evidence to support this
hypothesis as we could not identify consistent differences in
DNA methylation at viral insertion sites (unpublished data). Third,
HERV are expected to cause human diseases via the development
of genetic polymorphisms, essentially single-nucleotide (SNP) or
sequence insertions [15] but no HERV gene was reported by the
recent GWAS performed in large series of PBC cases and controls
[16]. Last and possibly most importantly, the proposed evidence
was obtained in a very small number of cases; the need for spec-
imens that are not readily available (i.e. lymph nodes) and the
complexity of the experimental approach (as in the case of viral
integration) do not appear sufﬁcient to overcome this major
limitation.
In conclusion, the available evidence that has been proposed
over the past decade falls well short of supporting a viral etiology
for PBC. The small numbers of cases included in all published
studies, as well as the conﬂicting results generated by different
groups, raise major concerns for this hypothesis. This hypothesis
may be another in the long series of retroviral associations pro-
posed for autoimmune diseases [17] that have failed to be con-
ﬁrmed independently or that have any practical implication.Conﬂict of interest
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